Gyre Therapeutics Q2 2026 net loss widens to $14.3 million; revenue falls 2% to $29.1 million
GYRE•Product sales mix shifts
ETUARY sales rose to $28.0 million from $23.5 million, while Etorel sales fell to $0.3 million from $1.6 million.
Q2 revenue and loss widen
Gyre Therapeutics posted Q2 revenue of $29.1 million, down 2% year over year, while GAAP basic EPS widened to a loss of $0.12.
GAAP net loss widened to $14.3 million from $2.2 million a year earlier, with operating loss deepening to $14.4 million.
Guidance and regulatory update
China’s CDE accepted an NDA for F351 in May; Gyre affirmed full-year 2026 revenue guidance of $100.5 million to $111.0 million.
Research and development costs increase
R&D expense jumped to $19.1 million from $8.4 million, driven by F351 Phase 3C review costs and an NDA-acceptance milestone payment.
